Sava Infond d.o.o. Has $5.79 Million Stake in Boston Scientific Corporation $BSX

Sava Infond d.o.o. raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 13.9% in the second quarter, Holdings Channel reports. The fund owned 53,870 shares of the medical equipment provider’s stock after acquiring an additional 6,560 shares during the period. Boston Scientific accounts for about 0.9% of Sava Infond d.o.o.’s portfolio, making the stock its 23rd biggest position. Sava Infond d.o.o.’s holdings in Boston Scientific were worth $5,786,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new position in Boston Scientific in the first quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new position in Boston Scientific in the first quarter valued at about $27,000. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific in the second quarter valued at about $37,000. Finally, Activest Wealth Management grew its stake in Boston Scientific by 6,216.7% in the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 373 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BSX. Canaccord Genuity Group boosted their target price on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday. Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. BTIG Research increased their price objective on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group increased their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Saturday, September 27th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $120.79.

Boston Scientific Stock Performance

Shares of NYSE BSX opened at $97.30 on Friday. The stock has a 50 day moving average price of $102.93 and a 200 day moving average price of $102.05. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market capitalization of $144.17 billion, a PE ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the firm posted $0.62 earnings per share. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.